ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center)

N/A

Report date: 2023/05/05 17:08:46

Base Information

Drug NameATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsImmunoproliferative DisordersLymphoproliferative DisordersLymphatic Diseases +[12] 
Inactive IndicationsImmune System DiseasesHodgkin DiseaseNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A